SG10201906400SA - Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof - Google Patents

Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Info

Publication number: SG10201906400SA
Authority: SG; Singapore
Prior art keywords: compounds; methods; pharmaceutical compositions; ppar agonists; compositions
Prior art date: 2015-10-07

Application number

SG10201906400SA

Other languages

English (en)

Inventor

Michael Downes

Ronald Evans

Arthur Kluge

Bharat Lagu

Masanori Miura

Sunil Panigrahi

Michael Patane

Susanta Samajdar

Ramesh Senaiar

Taisuke Takahashi

Original Assignee

Mitobridge Inc

Salk Inst Biological Studies

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-07

Filing date

2016-10-05

Publication date

2019-08-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201906400S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-10-05 Application filed by Mitobridge Inc, Salk Inst Biological Studies filed Critical Mitobridge Inc

2019-08-27 Publication of SG10201906400SA publication Critical patent/SG10201906400SA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SG10201906400SA 2015-10-07 2016-10-05 Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof SG10201906400SA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201562238629P	2015-10-07	2015-10-07
US201562243263P	2015-10-19	2015-10-19
US201662352348P	2016-06-20	2016-06-20

Publications (1)

Publication Number	Publication Date
SG10201906400SA true SG10201906400SA (en)	2019-08-27

Family

ID=57200096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201906400SA SG10201906400SA (en)	2015-10-07	2016-10-05	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Country Status (26)

Country	Link
US (6)	US10399958B2 (zh)
EP (3)	EP3359528B1 (zh)
JP (2)	JP6657413B2 (zh)
KR (2)	KR102667385B1 (zh)
CN (3)	CN113024467B (zh)
AU (3)	AU2016333963C1 (zh)
BR (1)	BR112018006866B1 (zh)
CA (1)	CA3000431A1 (zh)
CO (1)	CO2018004473A2 (zh)
DK (1)	DK3359528T3 (zh)
EA (1)	EA037371B1 (zh)
ES (3)	ES2949852T3 (zh)
HU (1)	HUE058154T2 (zh)
IL (3)	IL258225B (zh)
JO (3)	JO3738B1 (zh)
MA (2)	MA52098A (zh)
MX (3)	MX392523B (zh)
MY (1)	MY203081A (zh)
PH (1)	PH12018500762A1 (zh)
PL (1)	PL3359528T3 (zh)
PT (1)	PT3359528T (zh)
SG (1)	SG10201906400SA (zh)
TW (3)	TWI730006B (zh)
UA (1)	UA122237C2 (zh)
WO (1)	WO2017062468A1 (zh)
ZA (4)	ZA201802029B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102667385B1 (ko) *	2015-10-07	2024-05-21	미토브리지, 인크.	Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
ES2861503T3 (es)	2016-04-13	2021-10-06	Mitobridge Inc	Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos
MD3522880T2 (ro) *	2016-10-05	2021-03-31	Mitobridge Inc	Metode de tratare a leziunilor renale acute
PT3523283T (pt) *	2016-10-05	2021-09-10	Mitobridge Inc	Formas cristalinas e de sal de compostos agonistas de ppar
WO2021046081A1 (en) *	2019-09-05	2021-03-11	Rush University Medical Center	Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en)	2019-09-26	2023-04-25	Abionyx Pharma Sa	Compounds useful for treating liver diseases
WO2022189856A1 (en)	2021-03-08	2022-09-15	Abionyx Pharma Sa	Compounds useful for treating liver diseases
CA3221429A1 (en)	2021-06-02	2022-12-08	Astellas Pharma Inc.	Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en)	2022-01-25	2023-08-03	Reneo Pharmaceuticals, Inc.	Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en)	2022-02-21	2023-08-23	Som Innovation Biotech, S.A.	Compounds for use in the treatment of dystrophinopathies

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4228281A (en)	1977-09-23	1980-10-14	Ciba-Geigy Corporation	Dicarboxylic acids containing triazine rings
DE4123341A1 (de)	1991-07-15	1993-01-21	Thomae Gmbh Dr K	Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en)	1995-06-09	1995-08-02	Fujisawa Pharmaceutical Co	Benzamide derivatives
MXPA01008606A (es)	1999-02-26	2003-05-05	Merck & Co Inc	Compuestos de sulfonamida novedosos y uso de los mismos.
GB9919413D0 (en)	1999-08-18	1999-10-20	Zeneca Ltd	Chemical compounds
DK1311488T3 (da)	2000-08-17	2010-01-04	Pfizer Ltd	Substituerede imidazoler som tafia-inhibitorer
HRP20050181A2 (en)	2002-08-29	2006-03-31	Merck & Co. Inc.	Indoles having anti-diabetic activity
AU2003241836A1 (en)	2002-10-03	2004-04-23	Ono Pharmaceutical Co., Ltd.	Lpa receptor antagonists
WO2004060367A1 (en)	2002-12-30	2004-07-22	Fujisawa Pharmaceutical Co., Ltd.	Imidazole and triazole derivatives useful as selective cox-1 inhibitors
CN1886124A (zh)	2003-09-26	2006-12-27	日本烟草产业株式会社	抑制残余脂蛋白产生的方法
MX2007002391A (es)	2004-09-06	2007-04-23	Hoffmann La Roche	Derivados de 4-aminometil benzamida y su uso como inhibidores del factor viia.
AU2006289470A1 (en)	2005-02-15	2007-03-15	F. Hoffmann-La Roche Ag	Amide derivatives as PPAR activators
KR20080042170A (ko) *	2005-09-07	2008-05-14	플렉시콘, 인코퍼레이티드	Ｐｐａｒ 활성 화합물
KR20080094806A (ko)	2006-01-30	2008-10-24	트랜스테크 파르마, 인크.	치환된 이미다졸 유도체 및 이의 ＰＴＰａｓｅ 억제제로서의 용도
EP2001851A2 (en)	2006-03-28	2008-12-17	Novartis AG	Amide derivatives and their application for the treament of g protein related diseases
PL2014652T3 (pl)	2006-04-18	2015-02-27	Nippon Chemiphar Co	Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów
DE102006023336A1 (de)	2006-05-18	2007-11-22	Merck Patent Gmbh	1,5-Diphenyl-pyrazole II
CN101085772A (zh) *	2006-06-07	2007-12-12	上海艾力斯医药科技有限公司	一类具有PPARγ激动剂活性的化合物及其应用
JPWO2008093639A1 (ja)	2007-01-29	2010-05-20	武田薬品工業株式会社	ピラゾール化合物
GB2460784A (en)	2007-03-07	2009-12-16	Dong A Pharmtech Co Ltd	Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators,method of the same,and pharmaceutical composition
JP2008285452A (ja)	2007-05-21	2008-11-27	Ono Pharmaceut Co Ltd	ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
AU2008345009A1 (en)	2007-12-28	2009-07-09	The Salk Institute For Biological Studies	Methods for enhancing muscle performance and tone
EP2890313B1 (en)	2012-08-28	2016-09-21	KOC Universitesi	Bone plate
EP2981522A4 (en)	2013-04-05	2016-08-31	Salk Inst For Biological Studi	PPAR AGONISTS
EP3756661A1 (en)	2013-09-09	2020-12-30	vTv Therapeutics LLC	Use of a ppar-delta agonist for treating muscle atrophy
US20170305894A1 (en)	2014-10-08	2017-10-26	Mitobridge, Inc.	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057322A1 (en)	2014-10-08	2016-04-14	Salk Institute For Biological Studies	Ppar agonists and methods of use thereof
KR102667385B1 (ko) *	2015-10-07	2024-05-21	미토브리지, 인크.	Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
ES2861503T3 (es)	2016-04-13	2021-10-06	Mitobridge Inc	Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos
PT3523283T (pt) *	2016-10-05	2021-09-10	Mitobridge Inc	Formas cristalinas e de sal de compostos agonistas de ppar
MD3522880T2 (ro)	2016-10-05	2021-03-31	Mitobridge Inc	Metode de tratare a leziunilor renale acute
HUE054382T2 (hu) *	2016-12-30	2021-09-28	Mitobridge Inc	Poli-ADP ribóz polimeráz (PARP) inhibitorok

2016
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en active IP Right Grant
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-09-14 JO JOP/2020/0230A patent/JOP20200230A1/ar unknown
- 2020-09-14 JO JOP/2020/0231A patent/JOP20200231A1/ar unknown
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL275392A (en)	2020-07-30
ES2906379T3 (es)	2022-04-18
PT3359528T (pt)	2022-04-07
EP3770146C0 (en)	2024-07-24
US20240417383A1 (en)	2024-12-19
ES2949852T3 (es)	2023-10-03
CA3000431A1 (en)	2017-04-13
US10399958B2 (en)	2019-09-03
CN113004205B (zh)	2024-07-02
TW201943705A (zh)	2019-11-16
KR102667385B1 (ko)	2024-05-21
IL275392B (en)	2022-05-01
TWI730408B (zh)	2021-06-11
BR112018006866A2 (pt)	2018-10-16
CN113024467B (zh)	2024-08-06
ZA202003664B (en)	2022-08-31
JP6866514B2 (ja)	2021-04-28
MX2020011100A (es)	2022-05-23
AU2020281069B2 (en)	2022-10-27
TW202012375A (zh)	2020-04-01
AU2019283837A1 (en)	2020-01-16
EA037371B1 (ru)	2021-03-19
WO2017062468A8 (en)	2017-05-11
MX2018004295A (es)	2018-08-09
BR112018006866B1 (pt)	2023-11-21
IL258225B (en)	2021-08-31
MY203081A (en)	2024-06-07
IL275387B (en)	2021-08-31
EP3359528A1 (en)	2018-08-15
US20230373948A1 (en)	2023-11-23
AU2016333963C1 (en)	2021-05-27
KR20180095797A (ko)	2018-08-28
IL275387A (en)	2020-07-30
US10906885B2 (en)	2021-02-02
PH12018500762A1 (en)	2018-10-29
AU2016333963B2 (en)	2021-01-07
US20190084958A1 (en)	2019-03-21
WO2017062468A1 (en)	2017-04-13
AU2020281069A1 (en)	2021-01-07
TWI730006B (zh)	2021-06-11
ZA202003663B (en)	2022-08-31
DK3359528T3 (en)	2022-03-07
CN113004205A (zh)	2021-06-22
AU2016333963A1 (en)	2018-04-12
JO3738B1 (ar)	2021-01-31
MA52648A (fr)	2021-10-13
MX380281B (es)	2025-03-12
CN108349904B (zh)	2021-08-31
EA201890776A1 (ru)	2018-09-28
CN108349904A (zh)	2018-07-31
MA52098A (fr)	2021-01-27
KR20210126150A (ko)	2021-10-19
EP3770146B1 (en)	2024-07-24
KR102667386B1 (ko)	2024-05-21
MX2020011099A (es)	2022-05-23
JP2020075939A (ja)	2020-05-21
JP2018534355A (ja)	2018-11-22
EP3359528B1 (en)	2022-01-12
EP3770146A1 (en)	2021-01-27
TW201722919A (zh)	2017-07-01
JOP20200230A1 (ar)	2022-10-30
JP6657413B2 (ja)	2020-03-04
IL258225A (en)	2018-05-31
MX392523B (es)	2025-03-24
US11578052B2 (en)	2023-02-14
MX392524B (es)	2025-03-24
ZA201802029B (en)	2022-01-26
PL3359528T3 (pl)	2022-05-30
ZA202003662B (en)	2022-08-31
US20210253549A1 (en)	2021-08-19
CN113024467A (zh)	2021-06-25
NZ740846A (en)	2024-12-20
HK1257907A1 (zh)	2019-11-01
TWI742479B (zh)	2021-10-11
HUE058154T2 (hu)	2022-07-28
JOP20200231A1 (ar)	2022-10-30
UA122237C2 (uk)	2020-10-12
EP3795566B1 (en)	2023-04-19
ES2988059T3 (es)	2024-11-19
US20200157074A1 (en)	2020-05-21
CO2018004473A2 (es)	2018-09-20
AU2019283837B2 (en)	2020-12-24
US10479775B1 (en)	2019-11-19
EP3795566A1 (en)	2021-03-24
US20190337920A1 (en)	2019-11-07

Publication	Publication Date	Title
JOP20200230A1 (ar)	2022-10-30	ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
PH12020551043A1 (en)	2021-09-06	Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2021002321A (es)	2021-04-28	Nuevos metodos.
WO2017087608A8 (en)	2017-07-06	Modulators of ror-gamma
EP4497474A3 (en)	2025-04-23	Methods of treating rheumatic diseases using trimetazidine-based compounds
PH12016500866A1 (en)	2016-06-20	Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2016057658A8 (en)	2016-06-09	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2017009417A (es)	2017-12-07	Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
BR112018069930A2 (pt)	2019-02-05	agonistas de ppar, compostos, composições farmacêuticas, e métodos de uso dos mesmos
WO2015171558A3 (en)	2017-07-20	BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
PH12017500261A1 (en)	2017-07-10	Substituted bicyclic compounds
MA39765A (fr)	2017-02-01	Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2016004413A3 (en)	2016-03-03	Gls1 inhibitors for treating disease
MX2023005014A (es)	2023-05-16	Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2018014129A (es)	2019-04-29	Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
ZA202103209B (en)	2023-08-30	Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2016057660A8 (en)	2016-05-19	Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA201992619A2 (ru)	2020-03-31	Агонисты ppar, соединения, фармацевтические композиции и способы их применения
UA112357C2 (uk)	2016-08-25	Спосіб індивідуальної цільової терапії дефіциту вітаміну d у пацієнтів із захворюваннями кістково-м'язової системи
IN2014MU01184A (zh)	2015-10-02
IN2014MU01185A (zh)	2015-10-02
TH167851A (th)	2017-09-21	(s)-เพอร์ลินโดล และเกลือที่ยอมรับได้ทางเภสัชกรรมของมันสำหรับ การใช้ในยารักษาโรค